Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

This study has been completed.
Information provided by:
Novartis Identifier:
First received: August 5, 2008
Last updated: August 25, 2009
Last verified: August 2009
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.

Condition Intervention Phase
Primary Hyperaldosteronism
Drug: LCI699
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: A Pilot, Single-blind, Forced-titration Study to Assess the Hemodynamic and Hormonal Effects, Safety and Tolerability of the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Systolic blood pressure over a 7-week forced titration treatment period [ Time Frame: 7 weeks ]

Secondary Outcome Measures:
  • Plasma and urine hormone levels and electrolytes, diastolic blood pressure and drug pharmacokinetics over a 7-week forced titration treatment period [ Time Frame: 7 weeks ]

Estimated Enrollment: 12
Study Start Date: June 2008
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LCI696 1mg bid Drug: LCI699


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of primary hyperaldosteronism (PH) within the last 3 years, either with or without an aldosterone producing adenoma (APA).
  • Hypertension at screening

Exclusion Criteria:

  • Persistent hypokalemia
  • Renal impairment
  • Significant hepatic disease
  • Any surgical or medical condition which may significantly alter the absorption, distribution, metabolism or excretion of any drug substance

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00732771

Novartis Investigator Site
France, France
Sponsors and Collaborators
Principal Investigator: Novartis Novartis investigator site
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: External Affairs, Novartis Identifier: NCT00732771     History of Changes
Other Study ID Numbers: CLCI699A2206
Study First Received: August 5, 2008
Last Updated: August 25, 2009

Keywords provided by Novartis:
primary hyperaldosteronism
aldosterone synthase inhibitor

Additional relevant MeSH terms:
Adrenocortical Hyperfunction
Adrenal Gland Diseases
Endocrine System Diseases processed this record on May 25, 2017